Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Little

Showing results (1241-1250 of 1,276) with videos related to

Pageof 128
Sort By:
Scientific Data|May 11, 2016
Daphnia magna transcriptome by RNA-Seq across 12 environmental stressorsLuisa Orsini, Donald Gilbert, Ram Podicheti, et al.
Vaccine|November 30, 2025
Evaluation of the safety and immunogenicity of two fractional intradermal regimens of MVA-BN compared to standard dose vaccinationSharon E Frey, Lindsey R Baden, Hana M El Sahly, et al.
Kidney International|October 1, 2025
Changing paradigms of studies in kidney diseasesAdeera Levin, Allison Jaure, Dustin J Little, et al.
Journal of Medicinal Chemistry|September 16, 2008
Potent, orally bioavailable delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4'-piperidine]-4-yl)benzamide (ADL5859)Bertrand Le Bourdonnec, Rolf T Windh, Christopher W Ajello, et al.
Journal of Medicinal Chemistry|August 22, 2009
Spirocyclic delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-3-hydroxy-4-(spiro[chromene-2,4'-piperidine]-4-yl) benzamide (ADL5747)Bertrand Le Bourdonnec, Rolf T Windh, Lara K Leister, et al.
Frontiers in Aging Neuroscience|August 9, 2021
Comprehensive Evaluation of the 5XFAD Mouse Model for Preclinical Testing Applications: A MODEL-AD StudyAdrian L Oblak, Peter B Lin, Kevin P Kotredes, et al.
AIDS (London, England)|March 15, 2024
Impact of antiretroviral therapy during acute or early HIV infection on virologic and immunologic outcomes: results from a multinational clinical trialTrevor A Crowell, Justin Ritz, Lu Zheng, et al.
Nature Communications|January 8, 2025
Safety and immunogenicity of an optimized self-replicating RNA platform for low dose or single dose vaccine applications: a randomized, open label Phase I study in healthy volunteersChristian J Maine, Shigeki J Miyake-Stoner, Darina S Spasova, et al.
The Journal of Infectious Diseases|August 8, 2018
The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical StudiesGolnaz Namazi, Jesse M Fajnzylber, Evgenia Aga, et al.
Medrxiv : the Preprint Server for Health Sciences|June 19, 2023
Immunogenicity of a Two Dose Regimen of Moderna mRNA Beta/Omicron BA.1 Bivalent Variant Vaccine Boost in a Randomized Clinical TrialNadine G Rouphael, Angela R Branche, David J Diemert, et al.
Pageof 128

Showing results (1241-1250 of 1,276) with videos related to

Sort By:
Pageof 128
Scientific Data|May 11, 2016
Daphnia magna transcriptome by RNA-Seq across 12 environmental stressorsLuisa Orsini, Donald Gilbert, Ram Podicheti, et al.
Vaccine|November 30, 2025
Evaluation of the safety and immunogenicity of two fractional intradermal regimens of MVA-BN compared to standard dose vaccinationSharon E Frey, Lindsey R Baden, Hana M El Sahly, et al.
Kidney International|October 1, 2025
Changing paradigms of studies in kidney diseasesAdeera Levin, Allison Jaure, Dustin J Little, et al.
Journal of Medicinal Chemistry|September 16, 2008
Potent, orally bioavailable delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4'-piperidine]-4-yl)benzamide (ADL5859)Bertrand Le Bourdonnec, Rolf T Windh, Christopher W Ajello, et al.
Journal of Medicinal Chemistry|August 22, 2009
Spirocyclic delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-3-hydroxy-4-(spiro[chromene-2,4'-piperidine]-4-yl) benzamide (ADL5747)Bertrand Le Bourdonnec, Rolf T Windh, Lara K Leister, et al.
Frontiers in Aging Neuroscience|August 9, 2021
Comprehensive Evaluation of the 5XFAD Mouse Model for Preclinical Testing Applications: A MODEL-AD StudyAdrian L Oblak, Peter B Lin, Kevin P Kotredes, et al.
AIDS (London, England)|March 15, 2024
Impact of antiretroviral therapy during acute or early HIV infection on virologic and immunologic outcomes: results from a multinational clinical trialTrevor A Crowell, Justin Ritz, Lu Zheng, et al.
Nature Communications|January 8, 2025
Safety and immunogenicity of an optimized self-replicating RNA platform for low dose or single dose vaccine applications: a randomized, open label Phase I study in healthy volunteersChristian J Maine, Shigeki J Miyake-Stoner, Darina S Spasova, et al.
The Journal of Infectious Diseases|August 8, 2018
The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical StudiesGolnaz Namazi, Jesse M Fajnzylber, Evgenia Aga, et al.
Medrxiv : the Preprint Server for Health Sciences|June 19, 2023
Immunogenicity of a Two Dose Regimen of Moderna mRNA Beta/Omicron BA.1 Bivalent Variant Vaccine Boost in a Randomized Clinical TrialNadine G Rouphael, Angela R Branche, David J Diemert, et al.
Pageof 128